With clinical trials of Australia’s first mRNA coronavirus vaccine due to start in coming months, a key piece of equipment has arrived in Victoria to enable the critical manufacturing capability of mRNA vaccines to commence.
A new $1 million NanoAssemblr machine has been shipped in from Canada and will allow Boronia-based company IDT Australia to create the final product for mRNA vaccines, an official press release said.
It is the only machine of its kind in Australia and can process nanoparticles into final liquid drug form, sterilise the product and fill vials with mRNA vaccines.
The equipment will manufacture more than 150 doses for Phase 1 clinical trials of Australia’s first locally-developed mRNA coronavirus vaccine, as part of a trial run by the Monash Institute of Pharmaceutical Sciences (MIPS).
To make the trial possible, the Victorian Government has invested $5 million of support for the MIPS candidate.
IDT’s new mRNA manufacturing capability brings a level of expertise to Victoria that is currently unavailable anywhere else in Australia. The collaboration between MIPS, the Doherty Institute and IDT Australia reinforces the strong mRNA sector in Victoria, our research strength and manufacturing capability.
The MIPS candidate is Australia’s leading mRNA vaccine candidate, delivering next-generation vaccine support for ongoing COVID-19 protection, future pandemics and research capabilities for new drug and research breakthroughs.
The clinical trials are due to start in October 2021, with preliminary results from the trials expected in the first half of 2022.
Medical Research Jaala Pulford said, “Victoria leads the nation in mRNA expertise with universities, research institutes and industry working together to accelerate local mRNA development and manufacturing.
“We’ve acted swiftly to establish mRNA Victoria and committed $50 million to grow mRNA capability here, and we’re already making great progress.”
According to Monash University Professor of Pharmaceutical Biology Colin Pouton, “This machinery will allow us to work with IDT Australia to produce our second generation COVID-19 vaccine in preparation for Phase 1 clinical trials, which will be conducted through our partnership with the Doherty Institute.”
Follow The Indian Sun on Twitter | Instagram | Facebook
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
